Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Recently, the Company received a report from its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhifei Longcom") that the lyophilized inactivated Japanese encephalitis vaccine (human diploid cells) independently developed by Zhifei Longcom has obtained the clinical trial approval notice from the National Medical Products Administration (Notice No.: 2026LP01292), allowing the commencement of clinical trials for the prevention of epidemic Japanese encephalitis.